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  HIP
Impact of COVID-19 on clinical outcomes 
for patients with fractured hip
a multiCentRe OBseRvatiOnal COhORt stuDy
Aims
There are reports of a marked increase in perioperative mortality in patients admitted to 
hospital with a fractured hip during the COVID-19 pandemic in the UK, USA, Spain, and Ita-
ly. Our study aims to describe the risk of mortality among patients with a fractured neck of 
femur in England during the early stages of the COVID-19 pandemic.
Methods
We completed a multicentre cohort study across ten hospitals in England. Data were collect-
ed from 1 March 2020 to 6 April 2020, during which period the World Health Organization 
(WHO) declared COVID-19 to be a pandemic. Patients ≥ 60 years of age admitted with hip 
fracture and a minimum follow- up of 30 days were included for analysis. Primary outcome 
of interest was mortality at 30 days post- surgery or postadmission in nonoperative patients. 
Secondary outcomes included length of hospital stay and discharge destination.
Results
In total, 404 patients were included for final analysis with a COVID-19 diagnosis being made 
in 114 (28.2%) patients. Overall, 30- day mortality stood at 14.4% (n = 58). The COVID-19 
cohort experienced a mortality rate of 32.5% (37/114) compared to 7.2% (21/290) in the 
non- COVID cohort (p < 0.001). In adjusted analysis, 30- day mortality was greatest in pa-
tients who were confirmed to have COVID-19 (odds ratio (OR) 5.64, 95% confidence interval 
(CI) 2.95 to 10.80; p < 0.001) with an adjusted excess risk of 20%, male sex (OR 2.69, 95% CI 
1.37 to 5.29; p = 0.004) and in patients with ≥ two comorbidities (OR 4.68, CI 1.5 to 14.61; 
p = 0.008). Length of stay was also extended in the COVID-19 cohort, on average spending 
17.6 days as an inpatient versus 12.04 days in the non- COVID-19 group (p < 0.001).
Conclusion
This study demonstrates that patients who sustain a neck of femur fracture in combina-
tion with COVID-19 diagnosis have a significantly higher risk of mortality than would be 
normally expected.
Cite this article: Bone Joint Open 2020;1-11:697–705.
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Introduction
Despite a nationally imposed lockdown in 
the uK to combat COviD-19, the number 
of elderly patients admitted to hospital with 
fractured neck of femur (nOF) has remained 
fairly consistent1,2 the most recent report 
from the national hip Fracture Database 
for england, Wales and northern ireland 
concluded that for the year 2018 there were 
66,140 hip fractures, with an annualized 
30- day mortality of 6.1% across 175 trusts.3 
many patients who sustain a fractured nOF 
live in institutional care, where there is 
considerable risk of COviD-19 infection.4
trauma teams from the usa, spain, italy, 
and regions of the uK have all published their 
preliminary data on the effect COviD-19 has 
had on patients with fractured nOF, with all 
observing a marked increase in perioperative 
mortality.5-9 the team from the usa5 included 
136 nOF fracture patients from seven emer-
gency departments in the city and county 
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of new york. Of these, 31 were deemed COviD-19 posi-
tive with 11 (34.5%) patients not surviving beyond 30 
days post- surgery. similar mortality figures among their 
respective COviD-19 positive cohorts were observed by 
the spanish (30.4%, 7/23) and italian (43.75%, 4/31) 
teams.6,7 Within the uK, regional teams have published 
their own cohort results, identifying the prevalence of 
COviD-19 to range from 19.4% (82/422) in london to 
8.5% (27/317) in scotland, with 30- day mortality rates of 
30.5% (25/82) and 33.3% (9/27), respectively.8,9
this study aims to understand the perioperative clin-
ical outcome for elderly patients admitted to hospital 
with nOF fracture during the COviD-19 pandemic in the 
uK. Our primary objectives were to report the 30- day 
mortality for patients admitted to hospital with a frac-
tured nOF and report the prevalence of COviD-19 in this 
same cohort.
Methods
this was a multicentre observational cohort study 
involving a collaboration between ten orthopaedic 
units within england, with the region of West midlands 
supplying majority of centres (supplementary table i).
local collaborators from each centre collected data 
both retrospectively and prospectively from the 1 
march 2020 to 6 april 2020. the ten centres see approx-
imately 3,775 patients per year and so we anticipated 
400 to 435 patients in the study period. Patients were 
identified from handover lists, theatre operating, and 
local hospital digital systems. Patients ≥ 60 years of age 
admitted to ten hospitals who had sustained a fractured 
nOF were included in the study. We excluded patients 
with pelvic fractures, femoral shafts fractures and peri-
prosthetic fractures.
Ethics. the study was registered with the research and 
audit department of each participating uK centre. as 
we were using routinely collected anonymized data, for-
mal research ethics approval was not required. We used 
the online national Research ethics service decision tool 
(http://www. hra- decisiontools. org. uk) to confirm this.
Outcomes. Primary outcome was mortality at 30 days 
post- surgery. in addition to this, patients were followed 
up throughout their hospital stay in order to determine 
two cohorts. the COviD-19 cohort was based on ei-
ther a positive virology test (saRs- Cov-2 Rna reverse 
transcription polymerase chain reaction (Rt- PCR) de-
tection), or suspected signs, symptoms of COviD-19 
and/or imaging (chest radiograph or Ct). the non- 
COviD-19 cohort was based on either a negative virol-
ogy test (saRs- Cov-2 Rna Rt- PCR detection) or not ful-
filling the Public health england (Phe) criteria required 
for COviD-19 testing (applicable to all nhs hospitals 
during the time of this study).
Patients. We obtained data from ten centres which 
entered 433 patients. Of these, 404 patients met our 
inclusion criteria. COviD-19 diagnosis was made in 114 
patients (28.2%), with 109 Rt- PCR confirmations (27%), 
while five patients (1.2%) had their diagnosis confirmed 
from clinical signs and imaging. Fifty patients (12.4%) had 
negative Rt- PCR results whereas 245 patients (60.6%) 
did not meet Phe criteria for testing (Figure 1).
Confounding variables. We collected the following vari-
ables: age, sex, type of fracture, type of surgery, type of 
anaesthesia, asa (american society of anasthesiologists) 
grading, and side of injury. We also collected variables 
needed to calculate the nottingham hip Fracture score 
(nhFs); admission haemoglobin (hb), pre- admission 
living status, history of malignancy, abbreviated mental 
test score (amts), and number of comorbidities.10 the 
variables were input on a predesigned database and only 
those with < 20% missing data were reported within 
this study. in addition to this, the national hip Fracture 
Database was accessed by each institution and patients 
cross referenced for data completion.
Statistical analysis. Data are reported in accordance 
with strengthening the Reporting of Observational 
studies in epidemiology guidelines for Observational 
studies and statistical analyses and methods in the 
Published literature guidelines.11 Data were summa-
rized using descriptive statistics including count and 
percentages for categorical variables. Continuous var-
iables were described using the mean and sD. to test 
for differences in variables and outcomes, we used chi- 
squared and Fisher’s exact test for categorical variables 
and mann- Whitney u test for continuous variables as 
appropriate. a multivariate logistic regression model 
was fitted to assess the impact of COviD-19 on mortal-
ity at 30 days while adjusting for potential confound-
ers. the variables included in the multivariate logistic 
regression model were selected based on the statisti-
cally significant results of univariate logistic regression 
model including only one potential predictor. adjusted 
excess mortality rate was obtained as the difference 
of the averages of the predicted mortality probabil-
ities of the adjusted model assuming all patients had 
COviD-19 and assuming they did not have COviD-19. a 
two- sided p- value of < 0.05 was considered statistically 
significant. all analysis were performed using iBm sPss 
v. 26 (armonk, new york, usa) software for mac.12
Results
Cohort characteristics. Patients with a diagnosis of 
COviD-19 tended to be older (mean age 85.16 years 
(sD 8.67) vs 82.88 years (sD 8.59); p = 0.017, mann- 
Whitney u test), had larger proportion of males (37.7% 
(n = 43) vs 27.6% (n = 80); p = 0.046, chi- squared test), 
were more likely to come from institutional care (26.3% 
(n = 30) vs 20.3% (n = 59); p = 0.038, chi- squared test), 
as well as obtain higher mean asa (3.16 (sD 0.68) vs 
3.01 (0.63); p = 0.04, mann- Whitney u test) and mean 
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Fig. 1
Flow diagram depicting included patients for analysis. Rt- PCR, reverse transcription polymerase chain reaction.
nhFs (5.51 (sD 1.5) vs 5.08 (sD 1.54); p = 0.012, mann- 
Whitney u test) scores. While surgical interventions 
between the two groups proved similar, it was not-
ed that the two cohorts had equal distribution of pa-
tients managed non- operatively. table  i describes the 
other variables collected among further sub grouping 
for age, time to surgery, amts, asa, nhFs, of which 
none demonstrated statistical significance between the 
cohorts.
Clinical outcomes. table ii demonstrates significant dif-
ferences in 30- day postoperative mortality between the 
two groups. Overall, 58 patients (14.4%) did not sur-
vive beyond 30 days postoperatively, with the majority 
of these being in the COviD-19 cohort group (32.5% 
vs 7.2%; p = < 0.001). Conversely, most (48/58) of the 
deaths occurred while patients were still in a hospital. 
the mean length of stay was 17.66 days (sD 11.16), 
which proved five days longer in the COviD-19 group 
when compared to the non- COviD-19 group. in terms 
of timing to COviD-19 status (i.e. positive or negative 
result), in those that were tested this occurred predom-
inantly in the postoperative period (mean 9.23 days 
post- surgery (sD 8.06; -4 to 30). however, 15 patients 
underwent testing prior to their operation with five of 
them recording a positive COviD-19 result.
Modalities used to confirm COVID-19 status. table  iii, 
which corresponds to Figure  1, separates the different 
methods used to confirm COviD-19 status and their ef-
fects on mortality, revealing that patients who were con-
firmed positive by Rt- PCR (31.2%; n = 34) had a signifi-
cantly higher risk of death compared to negative (16%; 
n = 8) and not tested cohorts (5.4%; n = 13; p = 0.015, 
Fisher's exact test).
Predictors of outcome. Patients with a proven positive 
or suspected COviD-19 diagnosis had almost a six fold 
increased odds of mortality (OR = 5.64, 95% Ci 2.95 to 
10.80, p < 0.001) and an adjusted excess risk of 20% 
(supplementary table ii). likewise, when adjusted anal-
ysis was made to include the same significant unadjust-
ed covariates, the only predictors that remained relevant 
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Table I. Characteristics for COviD-19 status.
Variable Total
COVID-19 
(n = 114)
Non- COVID-19 
(n = 290) p- value
Mean age, yrs 
(SD)
83.52 (8.66) 85.16 (8.67) 82.88 (8.59) 0.017*
Age, n (%)
< 85 194 (48) 44 (38.6) 150 (51.7) 0.017†
≥ 85 210 (52) 70 (61.4) 140 (48.3)
Sex, n (%)
male 123 (30.4) 43 (37.7) 80 (27.6) 0.046†
Female 281 (69.6) 71 (62.3) 210 (72.4)
NOF type, n (%)
extracapsular 206 (51) 53 (46.5) 153 (52.8) 0.257†
intracapsular 198 (49) 61 (53.5) 137 (47.2)
Side of injury 
n (%)
Right 191 (47) 58 (50.9) 133 (45.9) 0.376†
left 209 (52) 54 (47.4) 155 (53.4)
unknown 4 (1) 2 (1.8) 2 (0.7)
Pre- admission 
residence, n 
(%)
home 309 (76.5) 80 (70.2) 229 (79) 0.038†
institution 89 (22) 30 (26.3) 59 (20.3)
unknown 6 (1.5) 4 (3.5) 2 (0.7)
Mean AMTS 
(SD)
7.09 (3.49) 6.58 (3.92) 7.27 (3.31) 0.086*
AMTS, n (%)
≥ 7 253 (62.6) 65 (57) 188 (64.8) 0.071†
≤ 6 128 (31.7) 38 (33.3) 90 (31)
unknown 23 (5.7) 11 (9.6) 12 (4.1)
Mean ASA grade 3.06 (0.65) 3.16 (0.68) 3.01 (0.63) 0.040*
ASA grade, n 
(%)
1 4 (1) 1 (0.9) 3 (1) 0.196†
2 54 (13.7) 12 (10.5) 42 (14.5)
3 257 (65.2) 76 (66.7) 181 (62.4)
4 75 (19) 30 (26.3) 45 (15.5)
5 3 (0.8) 1 (0.9) 2 (0.7)
6 1 (0.3) 1 (0.9) 0 (0)
1 to 2 58 (14.4) 12 (10.5) 46 (15.9) 0.293†
3+ 336 (83.2) 98 (86) 238 (82.1)
unknown 10 (2.5) 4 (3.5) 6 (2.1)
Mean NHFS (SD) 5.2 (1.54) 5.51 (1.5) 5.08 (1.54) 0.012*
NHFS, n (%)
≤ 5 219 (54.2) 57 (50) 162 (55.9) 0.287†
≥ 6 185 (45.8) 57 (50) 128 (44.1)
Malignancy, n 
(%)
yes 52 (13) 12 (10.5) 40 (13.8) 0.368†
no 347 (86) 101 (88.6) 246 (84.8)
unknown 5 (1) 1 (0.9) 4 (1.4)
Preoperative Hb 
< 100, n (%)
yes 50 (12) 17 (14.9) 33 (11.4) 0.328†
no 351 (87) 96 (84.2) 255 (87.9)
unknown 3 (1) 1 (0.9) 2 (0.7)
Comorbidities ≥ 
2, n (%)
() () ()
yes 303 (75) 92 (80.7) 211 (72.8) 0.087†
Continued
Variable Total
COVID-19 
(n = 114)
Non- COVID-19 
(n = 290) p- value
no 98 (24) 21 (18.4) 77 (26.6)
unknown 3 (1) 1 (0.9) 2 (0.7)
Surgery, n (%)
tha 13 (3.2) 4 (3.5) 9 (3.1) 0.073†
hemiarthroplasty 160 (39.6) 46 (40.4) 114 (39.3)
Dhs 121 (30.0) 26 (22.8) 95 (32.8)
im nail 91 (22.5) 33 (28.9) 56 (19.3)
Cannulated screws 6 (1.5) 0 (0) 6 (2.1)
Conservative 10 (2.5) 5 (4.4) 5 (1.7)
unknown 3 (0.7) 0 (0) 3 (1)
Anaesthesia, n 
(%)
Ga 219 (54.2) 63 (55.3) 156 (53.8) 0.376†
spinal 160 (39.6) 41 (36) 119 (41)
n/a 15 (3.7) 5 (4.4) 10 (3.4)
unknown 10 (2.5) 5 (4.4) 5 (1.7)
Mean time to 
surgery, days 
(SD)
1.46 (1.27) 1.49 (1.01) 1.45 (1.36) 0.756*
Time to surgery, 
n (%)
< 48 hrs 270 (66.8) 70 (61.4) 200 (69) 0.316†
≥ 48 hrs 118 (29.2) 38 (33.3) 80 (27.6)
unknown/n/a 16 (4.0) 6 (5.3) 10 (3.4)
*mann- Whitney u test.
†Chi- squared test.
amts, abbreviated mental test score; asa, american society of 
anesthesiologists score; Dhs, dynamic hip screw; Ga, general 
anaesthesia; hb, haemoglobin; im, intramedullary; n/a, not applicable; 
nhFs, nottingham hip Fracture score; nOF, neck of femur fracture; tha, 
total hip arthroplasty.
Table I. Continued
were positive COviD-19 diagnosis, male sex, and patients 
with ≥ two co- morbidities (table iv and Figure 2).
Discussion
Our study found that perioperative mortality was 14.4% 
(Ci 11.07 to 17.73) across the whole cohort of patients. 
however, the risk of perioperative mortality was higher 
among those patients who had a positive test or high 
clinical suspicion for COviD-19. Furthermore, the overall 
perioperative mortality in our cohort is higher than 
data reported in the national hip Fracture Database for 
england, Wales and northern ireland which reports an 
overall annualized 30- day mortality rate of 6.1%.3 Our 
data suggest an almost sixfold increased likelihood of 
mortality and an adjusted excess risk of 20% among hip 
fracture patients with a confirmed or suspected COviD-19 
status when compared to those without a COviD-19 
diagnosis. this also held true for male sex (OR 2.7, 95% 
Ci 1.37 to 5.29) and patients with two or more comor-
bidities (OR 4.7, 95% Ci 1.5 to 14.61) although with 
reduced odds ratios. nevertheless, such findings ought 
to be interpreted with caution as the model of adjusting 
the analysis to factors that proved significant individually 
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Table II. Outcome measures.
Variable Total COVID-19 (n = 114) Non- COVID-19 (n = 290) p- value
Status at discharge, n (%)
alive 358 (88.6) 84 (73.7) 274 (94.5) < 0.001*
Deceased 46 (11.4) 30 (26.3) 16 (5.5)
Status at 30 days postoperative, n (%)
alive 346 (85.6) 77 (67.5) 269 (92.8) < 0.001*
Deceased 58 (14.4) 37 (32.5) 21 (7.2)
Discharge destination, n (%)
home 184 (46) 42 (22.8) 142 (77.2) < 0.001*
Rehabilitation facility 71 (18) 17 (23.9) 54 (76.1)
Residential care 33 (8) 6 (18.2) 27 (81.8)
nursing home 36 (9) 8 (22.2) 28 (77.8)
Other hospital ward 17 (4) 3 (17.6) 14 (82.4)
inpatient 12 (3) 6 (50) 6 (50)
Deceased at discharge 45 (11) 31 (68.9) 14 (31.1)
unknown 6 (1) 1 (16.7) 5 (83.3)
Mean LOS, days (SD) 13.59 (8.81) 17.66 (11.16) 12.04 (7.17) < 0.001†
Mean time to COVID-19 diagnosis, days (SD) 9.23 (8.06) 10.1 (7.69) 7.26 (8.58) < 0.038†
*Chi- squared test
†mann- Whitney u test.
lOs, length of stay.
Table III. Differences in mortality between the different methods of 
COviD-19 confirmation at 30 days postoperatively.
COVID-19 status, 
n (%) Total
Alive
(n = 346)
Deceased
(n = 58) p- value*
Positive by Rt- PCR 109 (27.0) 75 (68.8) 34 (31.2) 0.015
negative by Rt- PCR 50 (12.4) 42 (84.0) 8 (16.0)
not tested 240 (59.4) 227 (94.6) 13 (5.4)
Clinical signs and 
imaging
5 (1.2) 2 (40.0) 3 (60.0)
*Fisher's exact test.
Rt- PCR, reverse transcription polymerase chain reaction.
can conclude different results depending on which 
factors were analyzed, as shown in supplementary table 
iii, which demonstrates an example when combining 
COviD-19 status, age, sex, tts, asa and nhFs, male sex 
no longer held the same statistical significance. Reassur-
ingly, irrespective of the differing covariates analyzed, 
positive COviD-19 status holds its clinically and statisti-
cally significant impact on mortality.
the exact cause of death was not collected and hence 
is a limitation of our study’s findings. there was hetero-
geneity in the way data was obtained with some centres 
reporting COviD-19 as a cause of death while others did 
not. hence we could not group the patients nor could we 
seek further clarification through official death certificate 
reports during the early phase of the COviD-19 pandemic 
when the healthcare system was under significant strain. 
Furthermore the effects on allied services such as those 
provided by orthogeriatric colleagues, whose involve-
ment in the care of hip fracture patients has proven to 
reduce mortality, was not determined within this study 
and is a further limitation.13
the COviDsuRG international collaborative group 
reported a 23.8% 30- day mortality rate among 1,128 
surgical patients with perioperative COviD-19 infec-
tion between 1 January 2020 and 31 march 2020. it 
is of note that of the 302 orthopaedic patients, 262 
were emergency. at least 115 were hip fracture patients 
(likely more) and though no sub- group analysis was 
reported, these rates of mortality are certainly similar to 
those observed in this study and others in significantly 
affected countries.5-9,14
Overall, 40% (159/404) of the included patients under-
went COviD-19 testing by Rt- PCR, with 96% (109/114) 
of the cases confirmed this way. unfortunately, with our 
study occurring during the early stages of the pandemic 
and as per Public health england guidance, routine labo-
ratory testing across the included centres was not carried 
out on all patients but instead was limited to only those 
who experienced symptoms suggestive of the COviD-19 
infection. hence, routine invasive testing of all patients 
regardless of clinical status would have required further 
ethical approval. additionally it would have further 
strained the healthcare system’s testing capacity which 
was already under considerable pressure. Routine testing 
of all emergency patients admitted to nhs hospitals only 
came in to force on the 27 april 2020.
a small number of patients (5/114, 1.2%) were 
included within our COviD-19 cohort as their clinical 
picture and imaging strongly favoured such a diagnosis. 
Given that COviD-19 diagnosis can be accurately made 
by appropriate imaging, we felt it valid to include such 
patients within our analysis.15 Conversely, 12.4% (50/114) 
of the patients proved negative by Rt- PCR. the moderate 
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Table IV. unadjusted and adjusted sensitivity analysis of predictors of 30 day postoperative mortality.
Characteristics n (% deceased)
Unadjusted analysis Adjusted analysis (R2 0.312)
OR (95% CI) p- value OR (95% CI) p- value
COVID-19 status
COviD-19 cohort 114 (32.5) 6.15 (3.40 to 11.13) < 0.001 5.64 (2.95 to 10.80) < 0.001
non COviD-19 cohort* 290 (7.2) n/a n/a n/a n/a
Age
mean n/a 1.05 (1.01 to 1.08) 0.015 n/a n/a
age < 85 yrs* 194 (9.8) n/a n/a n/a n/a
age ≥ 85 yrs 210 (18.6) 2.10 (1.17 to 3.78) 0.013 1.72 (0.87 to 3.41) 0.120
Sex
male 123 (22.8) 2.47 (1.40 to 4.35) 0.002 2.69 (1.37 to 5.29) 0.004
Female* 281 (10.7) n/a n/a n/a n/a
Time to surgery
mean n/a 1.32 (1.09 to 1.59) 0.004 n/a n/a
< 48 hrs* 270 (12.2) n/a n/a n/a n/a
≥ 48 hrs 118 (16.9) 1.47 (0.80 to 2.68) 0.214 1.20 (0.60 to 2.41) 0.606
unknown/ n/a 16 (8.6) 3.26 (1.07 to 9.99) 0.038 4.12 (0.94 to 18.05) 0.600
Pre- admission residence
home* 309 (11.7) n/a n/a n/a n/a
institutional care 89 (22.5) 2.20 (1.20 to 4.03) 0.011 1.44 (0.64 to 3.28) 0.377
unknown 6 (33.3) 3.79 (0.67 to 21.44) 0.132 1.16 (0.09 to 14.32) 0.911
AMTS
mean n/a 0.87 (0.80 to 0.94) < 0.001 n/a n/a
amts ≥ 7* 253 (10.3) n/a n/a n/a n/a
amts ≤ 6 128 (21.1) 2.33 (1.30 to 4.20) 0.005 2.13 (0.99 to 4.62) 0.540
unknown 23 (21.7) 2.43 (0.83 to 7.08) 0.105 1.64 (0.42 to 6.40) 0.479
ASA score
mean n/a 1.95 (1.26 to 3.02) 0.003 n/a n/a
asa 1 and 2* 58 (12.1) n/a n/a n/a n/a
asa 3+ 336 (15.2) 1.30 (0.56 to 3.03) 0.538 0.30 (0.09 to 1.02) 0.055
unknown 10 (0) not estimable 0.999 not estimable 0.999
NHFS
mean n/a 1.68 (1.34 to 2.09) < 0.001 n/a n/a
nhFs ≤ 5* 219 (9.1) 2.57 (1.44 to 4.60) 0.001 n/a n/a
nhFs ≥ 6 185 (20.5) n/a n/a n/a n/a
Malignancy
yes 52 (11.5) 0.69 (0.08 to 6.29) 0.741 n/a n/a
no* 347 (14.7) n/a n/a n/a n/a
unknown 5 (20) 0.59 (0.05 to 5.47) 0.588 n/a n/a
Pre- admission Hb
< 10 50 (24) 2.15 (1.05 to 4.41) 0.038 1.87 (0.80 to 4.41) 0.151
≥ 10* 351 (14.8) n/a n/a n/a n/a
unknown 3 (33) 3.4 (0.30 to 38.26) 0.322 6.13 (0.09 to 410.60) n/a
Comorbidities
< 2* 303 (5.1) n/a n/a n/a n/a
≥ 2 98 (17.2) 3.85 (1.49 to 9.94) 0.005 4.68 (1.50 to 14.61) 0.008
unknown 3 (50) 9.3 (0.72 to 120.73) 0.088 n/a n/a
*Reference.
amts, abbreviated mental test score; asa, american society of anesthesiologists score; Ci, confidence interval; nhFs, nottingham hip Fracture score; OR, 
odds ratio.
sensitivity of this test to provide false negative results of 
2% to 29% and with our data showing that the positive 
cohort had a 30- day postoperative mortality of 31.2%, 
and negative cohort 16%, it is possible that some of the 
confirmed negative patients were indeed positive and 
hence misplaced for final analysis.16,17 this is especially 
notable as the “not tested” cohort demonstrated a 
mortality rate of 5.4%, which is similar to that observed 
prior to the pandemic.3
Differences in length of hospital stay between the two 
cohorts were also observed, with the COviD-19 cohort 
group having a longer stay by a mean of 5.5 days. While 
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Fig. 2
adjusted analysis for predictors of 30 day postoperative mortality. amts, abbreviated mental test score, asa, american society of anesthesiologists grade, 
hb,haemoglobin, tts, time to surgery.
our study was not designed to discern the true reason 
behind this, it would not be unfair to assume that the 
positive group were significantly sicker, requiring greater 
input, effort and time for their care and recovery. Relatedly, 
with the non- COviD-19 cohort technically being asymp-
tomatic and hence assumed safer for discharge and with 
hospitals under pressure to retain appropriate capacity 
for the anticipated COviD-19 peak in early april 2020, it is 
possible that some of the observed length of hospital stay 
disparity could be construed to this. Reiterating the false- 
negative issue with testing, a proportion of otherwise 
COviD-19 positive patients might have been discharged 
to institutional care given that the non- COviD-19 group 
(55/69; 80%) accounted for a large proportion of these. 
equally, COviD-19 doesn’t always lead to a clinical mani-
festation with up to 40% of patients remaining asymptom-
atic throughout the duration of COviD-19 infection.18,19 
From 15 april 2020 it became mandatory for all patients 
being discharged to care institutions to undergo routine 
testing prior to discharge from hospital.20
With regard to patients who underwent COviD-19 
testing, we found that the majority of testing and subse-
quent confirmation of a positive result occurred in the 
postoperative period (mean 9.23 days after surgery (sD 
8.06). One could hypothesize that their infection was 
perhaps secondary to nosocomial spread. however, 
given the incubation period of COviD-19 (which ranges 
from 2 to 14 days), such conjecture would be incorrect. it 
is just as likely that these patients acquired the infection 
in the community prior to admission.21
We are also aware that there has been a wide regional 
variation of COviD-19 prevalence and hence our findings 
must be applied cautiously across the whole of the uK. 
the West midlands, which is one of the most populous 
regions in the uK with 5.9 million inhabitants, was partic-
ularly hard hit.22 at the time of undertaking this work, it 
was the second- worst hit region with COviD-19 disease 
behind london (43.2 deaths per 100,000).23 interest-
ingly, there were no observed deaths in the other centre 
from the northwest of england. Conversely, the two 
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uK- based published studies have reported differences 
in COviD-19 prevalence among their cohorts with the 
scottish team recording a prevalence of 9% while the 
team from london reported 18%, which are considerably 
different to our figure of 28%.8,9
the testing strategy in the uK has changed signifi-
cantly since the undertaking of this study; however, the 
prevalence of the disease has also evolved. therefore, 
though future studies within the uK may provide us 
with a more accurate reflection of disease prevalence, 
this will be at a very different stage of the pandemic. 
serological antibody testing has now also been intro-
duced and in time this may give us a clearer idea of 
previous infection rates and regional variability. addi-
tionally, this study was undertaken during the peak of 
the pandemic in england (R number = 4) and therefore 
does not reflect the current situation where rates of new 
infection and mortality have fallen considerably. never-
theless, COviD-19 prevalence is ever evolving given the 
developments of september 2020 reporting an increase 
in the R number from < 1 toward 1.5, hence the findings 
reported here and elsewhere maintain their importance 
and relevance.24
the limitations of this study have been alluded to 
above in terms of data collection, testing variability, 
sensitivity and geographical differences in COviD-19 
prevalence. these were unfortunately unavoidable, 
with testing variability being a product of Public health 
england policy.
although our sample size may be deemed small given 
the wide confidence intervals this is nevertheless one of the 
largest studies looking at the impact of COviD-19 on hip 
fracture patients worldwide, containing more or an equiv-
alent number of patients to the published studies to date.5-9 
additionally, the presence of the non- COviD-19 compar-
ator allows differences among the two groups to be high-
lighted unlike the COviDsuRG Collaborative who reviewed 
only COviD-19 surgical cases.14
the findings from this study clearly demonstrate the 
significant additional risk to hip fracture patients who 
develop COviD-19 infection within 30 days of surgery 
(or admission if managed nonoperatively). it also 
highlights factors associated with acquiring COviD-19 
infection, although the results may not present a 
new or surprising finding given the detrimental effect 
COviD-19 has had on the world’s population. We 
nevertheless feel that this piece of work is important, 
as it allows us to counsel patients and their families of 
the potential risks of being admitted with a hip fracture 
during a period when hospitals are placed under pres-
sure from highly infectious diseases.
Twitter
Follow C. Thomas @doctorthomaschr
Follow K. Mangat @mr_upper_limb
Supplementary material
  tables displaying regional distribution of patients, 
adjusted excess mortality risk analysis, and unad-
justed and adjusted sensitivity analysis of predic-
tors of 30- day postoperative mortality.
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